Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial

NCT00082082 is registered in ClinicalTrials.gov with SciClone Pharmaceuticals as lead sponsor.

NCT NCT00082082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00082082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial
Lead sponsor
SciClone Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular